Amarin Corp Plc (AMRN)

[ziploc_1]

The patented method of encapsulation used in Vascepa to protect the pure EPA from being oxidized...thereby preventing its loss of effectiveness in preventing CVD events... distinguishes Vascepa from gV, which does not use it.

Mochida's MD-2119 does not make use of Amarin's patented method of encapsulation, but I'm sure Mochida and Amarin could reach an agreement for both of them to use it...for both the mono drug and the combo drug.